Abstract: The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.

Abstract: The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.

Abstract: The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.

Abstract: Comminuted particles of iridescent laminate film are prepared by supporting the film on a strippable substrate prior to the processing of the film into particulate form.

Abstract: A transparent iridescent thermoplastic resinous laminate film having at least 10 very thin layers of substantially uniform thickness, said layers being generally parallel, the contiguous adjacent layers being of different transparent thermoplastic resinous materials of which one is a naphthalate-based polyester or copolyester resin, the contiguous adjacent layers differing in refractive index by at least about 0.03.

Abstract: Comminuted particles of iridescent laminate film are prepared by supporting the film on a strippable substrate prior to the processing of the film into particulate form.

Abstract: Comminuted particles of iridescent laminate film are prepared by supporting the film on a strippable substrate prior to the processing of the film into particulate form.

Abstract: A transparent thermoplastic resinous laminate film is disclosed having at least 10 very thin layers of substantially uniform thickness, said layers being generally parallel, the contiguous adjacent layers being of different transparent thermoplastic resinous materials of which one is a naphthalate-based polyester or copolyester resin, the contiguous adjacent layers differing in refractive index by at least about 0.03.

Abstract: An oxygen and moisture impermeable multilayer barrier film which is free of halogens and which may be produced by coextrusion or lamination techniques is provided. The film provides excellent adhesion between layers, has quietness, odor barrier, and softness characteristics, and provides a heat sealable surface for the fabrication of bags. The barrier film includes a halogen-free barrier layer and at least one heat sealable skin layer. The heat sealable skin layer includes either a thermoplastic polyurethane, a substantially linear copolymer of ethylene and an .alpha.-olefin having a density in the range of from about 0.87-0.92 gm/cc and from about 0.01 to 3 long chain branches/1000 carbon atoms along the polymer backbone, a homogeneously-branched linear polyolefin resin, or a blend of an ultra low density polyolefin resin with a copolymer of ethylene and vinyl acetate.

Abstract: An oxygen and moisture impermeable multilayer barrier film is provided including a barrier layer comprising a homopolymer of vinylidene chloride or a copolymer of vinylidene chloride and vinyl chloride or methyl methacrylate. The barrier layer is coextruded with or laminated to at least one heat sealable skin layer comprising a thermoplastic polyurethane, a substantially linear copolymer of ethylene and an .alpha.-olefin, or a homogeneously-branched linear olefin resin to form the barrier film. The multilayer film may be used for reusable ostomy bags, for systems for the transdermal delivery of drugs, and for heat sealable bags used in packaging.

Abstract: An oxygen and moisture impermeable multilayer barrier film is provided including a barrier layer comprising a homopolymer of vinylidene chloride or a copolymer of vinylidene chloride and vinyl chloride or methyl methacrylate. The barrier layer may be coated onto or coextruded with a water soluble film layer comprising a blend of a water soluble polymer such as polyvinyl alcohol, polycaprolactone, or polyethyloxozaline and a thermoplastic polyurethane. The multilayer film may be used for reusable or disposable ostomy bags and for heat sealable bags used in packaging agricultural chemicals, detergents, and other household chemicals.